VIVUS and Teva Enter Into Settlement Over Weight Management Generic

Teva

VIVUS has announced entering into a settlement agreement with Actavis Laboratories, a subsidiary of Teva. Actavis was preparing to launch a generic version of Qsymia, a weight management drug produced by VIVUS. The settlement agreement dictates that Actavis will not be able to sell a generic version of the drug until Dec 1, 2024. Patent litigation between the two companies had been ongoing for three years prior to the agreement, beginning in the US District Court for the District of New Jersey in 2014.

Read the source article at Nasdaq.com

About the Author

Related Posts

Leave a Reply

*